Potential Therapeutic Application for Nicotinic Receptor Drugs in Movement Disorders
Authors:
- 17 August 2018
- journal article
- review article
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 21 (3) , 357-369
Abstract
Emerging studies indicate that striatal cholinergic interneurons play an important role in synaptic plasticity and motor control under normal physiological conditions, while their disruption may lead to movement disorders. Here we discuss the involvement of the cholinergic system in motor dysfunction, with a focus on the role of the nicotinic cholinergic system in Parkinson’s disease and drug-induced dyskinesias. Evidence for a role for the striatal nicotinic cholinergic system stems from studies showing that administration of nicotine or nicotinic receptor drugs protects against nigrostriatal degeneration and decreases L-dopa-induced dyskinesias. In addition, nicotinic receptor drugs may ameliorate tardive dyskinesia, Tourette’s syndrome and ataxia, although further study is required to understand their full potential in the treatment of these disorders. A role for the striatal muscarinic cholinergic system in movement disorders stems from studies showing that muscarinic receptor drugs acutely improve Parkinson’s disease motor symptoms, and may reduce dyskinesias and dystonia. Selective stimulation or lesioning of striatal cholinergic interneurons suggests they are primary players in this regulation, although multiple central nervous systems appear to be involved. Accumulating data from preclinical studies and clinical trials suggest that drugs targeting CNS cholinergic systems may be useful for symptomatic treatment of movement disorders. Nicotinic cholinergic drugs, including nicotine and selective nAChR receptor agonists, reduce L-dopa-induced dyskinesias, as well as antipsychotic-induced tardive dyskinesia, and may be useful in Tourette’s syndrome and ataxia. Subtype selective muscarinic cholinergic drugs may also provide effective therapies for Parkinson’s disease, dyskinesias and dystonia. Continued studies/trials will help address this important issue.Keywords
Funding Information
- National Institutes of Health
This publication has 204 references indexed in Scilit:
- Meta‐analysis of early nonmotor features and risk factors for Parkinson diseaseAnnals of Neurology, 2012
- Nicotine Reduces Antipsychotic-Induced Orofacial Dyskinesia in RatsThe Journal of Pharmacology and Experimental Therapeutics, 2012
- α6β2* and α4β2* Nicotinic Acetylcholine Receptors As Drug Targets for Parkinson’s DiseasePharmacological Reviews, 2011
- Environmental tobacco smoke and Parkinson's diseaseMovement Disorders, 2011
- Varenicline Is a Potent Agonist of the Human 5-Hydroxytryptamine3 ReceptorThe Journal of Pharmacology and Experimental Therapeutics, 2011
- Nicotine Reduces l-DOPA-Induced Dyskinesias by Acting at β2* Nicotinic ReceptorsThe Journal of Pharmacology and Experimental Therapeutics, 2011
- Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian ratsNeuropharmacology, 2011
- Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitryNature, 2010
- Nicotinic Receptor-Mediated Reduction in l-DOPA-Induced Dyskinesias May Occur via DesensitizationThe Journal of Pharmacology and Experimental Therapeutics, 2010
- It is not “either/or”: Activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and moodProgress in Neurobiology, 2008